Doxorubicin–Trabectedin with Trabectedin Maintenance in Leiomyosarcoma

Among patients with leiomyosarcoma, a combination of doxorubicin and trabectedin with prolonged trabectedin maintenance therapy led to longer overall survival than doxorubicin alone (median, 33 vs. 24 months).

Saved in:
Bibliographic Details
Published in:The New England journal of medicine Vol. 391; no. 9; pp. 789 - 799
Main Authors: Pautier, Patricia, Italiano, Antoine, Piperno-Neumann, Sophie, Chevreau, Christine, Penel, Nicolas, Firmin, Nelly, Boudou-Rouquette, Pascaline, Bertucci, François, Lebrun-Ly, Valérie, Ray-Coquard, Isabelle, Kalbacher, Elsa, Bompas, Emmanuelle, Collard, Olivier, Isambert, Nicolas, Guillemet, Cécile, Rios, Maria, Le Cesne, Axel, Balleyguier, Corinne, Archambaud, Baptiste, Duffaud, Florence
Format: Journal Article
Language:English
Published: United States Massachusetts Medical Society 05.09.2024
Subjects:
Aged
Antineoplastic Combined Chemotherapy Protocols - administration & dosage
Antineoplastic Combined Chemotherapy Protocols - adverse effects
Cancer
Chemotherapy
Combination therapy
Disease control
Doxorubicin
Doxorubicin - administration & dosage
Doxorubicin - adverse effects
Female
Gynecologic Oncology
Gynecology
Hematology
Humanities and Social Sciences
Humans
Kaplan-Meier Estimate
Leiomyosarcoma - drug therapy
Leiomyosarcoma - mortality
Leiomyosarcoma - pathology
Life Sciences
Maintenance Chemotherapy
Medical prognosis
Metastases
Metastasis
Methodology
Methods and statistics
Middle Aged
Neoplasm Staging
Neutropenia
Obstetrics
Oncology
Other Statistics
Patients
Progression-Free Survival
Sarcoma
Soft Tissue Neoplasms - drug therapy
Soft Tissue Neoplasms - mortality
Soft Tissue Neoplasms - pathology
Statistical analysis
Statistics
Survival
Survival Analysis
Trabectedin - administration & dosage
Trabectedin - adverse effects
Treatments in Oncology
Uterine Neoplasms - drug therapy
Uterine Neoplasms - mortality
Uterine Neoplasms - pathology
Uterus
ISSN:0028-4793, 1533-4406, 1533-4406
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Among patients with leiomyosarcoma, a combination of doxorubicin and trabectedin with prolonged trabectedin maintenance therapy led to longer overall survival than doxorubicin alone (median, 33 vs. 24 months).
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ObjectType-Undefined-3
ISSN:0028-4793
1533-4406
1533-4406
DOI:10.1056/NEJMoa2403394